Kinetics of gallium nitrate, a new anticancer agent

Area of Science:

• Oncology
• Pharmacology
• Nephrology

Background:

• Disseminated neoplasms often require novel therapeutic agents.
• Gallium nitrate is an investigational agent with potential antineoplastic activity.
• Understanding gallium nitrate pharmacokinetics is crucial for its clinical application.

Purpose of the Study:

• To characterize the pharmacokinetic profile of gallium nitrate in patients with refractory neoplasms.
• To evaluate the influence of renal function and prior chemotherapy on gallium nitrate disposition.
• To determine gallium nitrate's plasma half-life, volume of distribution, and clearance.

Main Methods:

• Phase I clinical trial involving 8 patients with advanced cancers.
• Intravenous administration of gallium nitrate at doses ranging from 300 to 600 mg/m2.
• Colorimetric determination of gallium concentrations in biological fluids (plasma, urine).

Main Results:

• Gallium exhibited biphasic plasma disappearance with a terminal half-life of approximately 25.1 hours in patients with normal renal function.
• Volume of distribution averaged 1.19 L/kg, indicating distribution in total body water with potential compartment localization.
• Total plasma clearance was 0.65 ml/kg/min in patients with normal renal function; urinary excretion averaged 35% within 24 hours.
• Altered gallium kinetics were observed in patients with acute renal dysfunction and those with prior metal chemotherapy exposure.

Conclusions:

• Gallium nitrate demonstrates a prolonged terminal elimination half-life, suggesting potential for accumulation.
• Renal function significantly impacts gallium nitrate excretion and overall pharmacokinetic profile.
• Prior exposure to metal-based chemotherapy may alter gallium nitrate kinetics, necessitating careful patient selection and dosing adjustments.